BioCentury | Jun 26, 2020
Finance

June 25 Quick Takes: Chi-Med rakes in $100M; plus bank rules rolled back, newco DeCART has June ties and more

...first program will use Nurix’s NX-0255, a small molecule inhibitor of the E3 ubiquitin ligase Cbl-b...
...Therapeutics Inc. (NASDAQ:MGTA), $60 million; and Evelo Biosciences Inc. (NASDAQ:EVLO), $45 million. Targets Cbl-b - Casitas B cell lymphoma-b BioCentury...
BioCentury | May 21, 2020
Finance

HotSpot heads for clinic with $65M series B round to develop allosteric modulators

...protein classes -- kinases, transcription factors and E3 ligases. A preclinical E3 ligase program targeting Cbl-b...
...in private capital, including a $400 million series C round in 2018. Targets Cbl-b - Casitas B cell lymphoma-b...
BioCentury | Mar 13, 2020
Finance

Nurix raises $120M in week’s second major protein degradation financing

...space have all gone after different targets,” he said. The second immuno-oncology program inhibits the CBL-B...
...profound effects on biology.” Nurix is aiming to submit an IND by 2H20 for the CBL-B...
...BTK - Bruton’s tyrosine kinase CBL-B - Casitas B cell lymphoma-b Lauren Martz, Senior Editor Nurix Therapeutics Inc. Bruton's tyrosine kinase (Btk) Casitas B cell lymphoma-b (Cbl-b) Protein...
BioCentury | Oct 26, 2019
Product Development

How a KRAS program transformed Mirati's story

With the first clinical data due on Mirati’s KRAS inhibitor next week, the market will get its first chance to justify -- or otherwise -- the large chunk of the company’s $3 billion valuation tied...
BioCentury | Sep 13, 2019
Tools & Techniques

Getting higher-quality hits out of DNA-encoded libraries

...working with an external supplier,” Hansen said. Nurix expects to start clinical testing of a Cbl-b...
...San Francisco, Calif. X-Chem Inc., Waltham, Mass. Targets Btk - Bruton’s tyrosine kinase Cbl-b - Casitas B cell lymphoma-b...
...plc HotSpot Therapeutics Inc. Nurix Therapeutics Inc. Roche Pfizer Inc. The Scripps Research Institute University of California Irvine X-Chem Inc. Bruton's tyrosine kinase (Btk) Casitas B cell lymphoma-b (Cbl-b) Receptor-interacting...
BioCentury | Apr 11, 2019
Emerging Company Profile

Nurix: Two sides of protein degradation

...program and royalties. The partners disclosed data from the program’s first target, the E3 ligase Cbl-b...
...last month ahead of the American Association for Cancer Research (AACR) meeting. In T cells, Cbl-b...
...Mass. Nurix Therapeutics Inc., San Francisco, Calif. Targets Btk - Bruton’s tyrosine kinase Cbl-b - Casitas B cell lymphoma-b...
BioCentury | Oct 19, 2018
Company News

Revolution acquiring Warp Drive

...Src homology protein tyrosine phosphatase 2 (SHP-2; SHPTP2; PTPN11) and casitas B cell lymphoma b (Cbl-b...
BioCentury | Oct 16, 2018
Company News

Revolution acquiring fellow Third Rock company Warp Drive

...Src homology protein tyrosine phosphatase 2 (SHP-2; SHPTP2; PTPN11) and casitas B cell lymphoma b (Cbl-b...
BioCentury | Aug 1, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: July 2018

New Therapeutic Targets and Biomarkers: July 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during July 2018. Therapeutic targets are defined as any protein, gene or other...
BioCentury | Jul 18, 2018
Distillery Techniques

Biomarkers

TECHNOLOGY: Gene profiling Mutations in hematopoiesis-associated genes could help predict the risk of AML. Genomic sequencing of 124 patients who later developed AML and 686 healthy volunteers identified associations between the disease and mutations in...
Items per page:
1 - 10 of 63